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Abstract
Background: Chemotherapy for glioblastoma (GBM) patients is compromised in part by poor perfusion in the
tumor. The present study evaluates how treatment with liposomal formulation of irinotecan (Irinophore C™), and
other liposomal anticancer drugs, influence the tumor vasculature of GBM models grown either orthotopically or
subcutaneously.
Methods: Liposomal vincristine (2 mg/kg), doxorubicin (Caelyx
®; 15 mg/kg) and irinotecan (Irinophore C™; 25 mg/
kg) were injected intravenously (i.v.; once weekly for 3 weeks) in Rag2M mice bearing U251MG tumors. Tumor
blood vessel function was assessed using the marker Hoechst 33342 and by magnetic resonance imaging-
measured changes in vascular permeability/flow (Ktrans). Changes in CD31 staining density, basement membrane
integrity, pericyte coverage, blood vessel diameter were also assessed.
Results: The three liposomal drugs inhibited tumor growth significantly compared to untreated control (p < 0.05-
0.001). The effects on the tumor vasculature were determined 7 days following the last drug dose. There was a 2-3
fold increase in the delivery of Hoechst 33342 observed in subcutaneous tumors (p < 0.001). In contrast there was
a 5-10 fold lower level of Hoechst 33342 delivery in the orthotopic model (p < 0.01), with the greatest effect
observed following treatment with Irinophore C. Following treatment with Irinophore C, there was a significant
reduction in Ktrans in the orthotopic tumors (p < 0.05).
Conclusion: The results are consistent with a partial restoration of the blood-brain barrier following treatment.
Further, treatment with the selected liposomal drugs gave rise to blood vessels that were morphologically more
mature and a vascular network that was more evenly distributed. Taken together the results suggest that
treatment can lead to normalization of GBM blood vessel the structure and function. An in vitro assay designed to
assess the effects of extended drug exposure on endothelial cells showed that selective cytotoxic activity against
proliferating endothelial cells could explain the effects of liposomal formulations on the angiogenic tumor
vasculature.
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Glioblastoma (GBM) tumors are largely refractory to
systemic treatments; the median survival time for
patients with GBM is 10 months and the 2-year survival
rate is less than 10%. Chemotherapy for GBM is com-
promised in part by the blood-brain barrier limiting
drug access to the malignant cells. In addition, pre-clini-
cal models showed that GBM tumors are poorly per-
fused [1,2] due to factors such as reduced blood flow
rates, elevated hematocrit and interstitial fluid pressure,
and an increase in geometric resistance [3-6], all of
which impede drug delivery to the tumor tissue. Strate-
gies which improve vascular function in GBM tumors
should improve the delivery of other drugs capable of
crossing the blood brain barrier and this should be asso-
ciated with an increase in therapeutic activity.
Our laboratory has previously characterized and
described the effects of a liposomal formulation of irino-
tecan (Irinophore C™) [7,8]. Encapsulation of irinotecan
into liposomes improved the pharmacokinetic profile of
the drug and its active metabolite, SN-38. More specifi-
cally, administration of Irinophore C™ resulted in a
1000-fold increase in the area-under-the-curve of
plasma irinotecan concentration when compared to free
drug (Camptosar). In addition, following irinophore C™
injection, the plasma levels of SN-38 were maintained at
concentrations that were up to 40-fold higher than that
achieved following injection of free drug [7]. Following
irinophore C™ treatment, the s.c. (subcutaneous) color-
ectal tumors (HT-29) exhibited more functional tumor
blood vessels, reduced hypoxia, and increased tumor
perfusion. Importantly, these changes in tumor vascula-
ture were associated with increased tumor uptake of
doxorubicin and 5-FU given intravenously [8]. The latter
data were consistent with the idea that the tumor vascu-
lature in the treated tumors acquires a more “normal-
like” function; an effect of anti-angiogenic therapies
described as ‘normalization’ [9,10].
The primary goal of the studies reported here was to
determine whether Irinophore C™ is efficacious in
models of GBM, and whether treatment with this drug
formulation would also result in normalization of GBM
vasculature. The effects of Irinophore C™ on the
growth rates and vascular function of the HT-29 color-
ectal cancer model was attributed to significant
increases in the drug circulation lifetime and plasma
concentration when encapsulated in liposomes [7,8]. We
further reasoned that liposomal formulations of other
drugs with known activity against proliferating endothe-
lial cells should have preferential cytotoxicity towards
angiogenic tumor vessels and could potentially also ‘nor-
malize’ the chaotic and erratic vasculature of tumors.
Thus, part of these studies assessed the effects of liposo-
mal vincristine [11] and doxorubicin (Caelyx
®)o n
tumor vasculature. Vincristine has previously been
shown to be active against proliferating endothelial cells
[12]. Liposomal formulations of doxorubicin have also
been shown to have direct effects on tumor associated
vasculature [13-15].
The data reported here assess the effects of Irinophore
C™,C a e l y x
® (a commercially available and FDA-
approved liposomal formulation of doxorubicin), and
liposomal vincristine on tumor vasculature in subcuta-
neous and orthotopic models of GBM. The results indi-
cate that Irinophore C™ was the most active
formulation when using treatment endpoints based on
changes in tumor size as well as tumor vascular mor-
phology and function in GBM grown subcutaneously
and orthotopically. The effects were consistent with the
idea that following treatment, there was normalization
of tumor vasculature. In the subcutaneous tumors, vas-
cular ‘normalization’ was associated with increased
tumor uptake of Hoechst 33342, while in the orthotopic
glioma tumors, treatment-induced vascular ‘normaliza-
tion’ was associated with decreased tumor uptake of
Hoechst 33342.
Methods
Cell culture
Adult dermal human microvascular endothelial cells (d-
HMVEC; Cambrex Bio Science, Walkersville, MD),
Human brain microvascular endothelial cells (HBMEC;
ScienCell Research Laboratories, San Diego, California)
and U251MG glioblastoma cells (American Type Cul-
ture Collection, Manassas, VA) were characterized and
authenticated by the cell banks using immunofluores-
cent methods and used for a maximum of eight passages
for the endothelial cells and fifteen passages for
U251MG. Stock cells lines were maintained in the
absence of penicillin and streptomycin and screened for
mycoplasma prior to preparing a stock of cells that were
frozen for use in experiments. D-HMVEC cells were
maintained in Endothelial Cell Basal Medium-2 (Clo-
netics
®, Lonza, Basel, Switzerland) supplemented with 5
ng/mL Fibroblast Growth Factor, 20 ng/mL Vascular
Endothelial Growth Factor, 10 ng/mL Epidermal Growth
Factor (Clonetics
®, Lonza), 10 unit/mL Heparin (Phar-
maceutical Partners of Canada) 1% L-glutamine, 1%
penicillin/streptomycin (Stem Cell Technologies, Van-
couver, BC, Canada) and 10% Fetal Bovine Serum (FBS;
Hyclone, Logan, UT), and plated in 1% gelatin (Sigma,
Oakville, ON, Canada) pre-coated dish. HBMEC cells
were maintained in Endothelial Cell Medium supple-
mented with Endothelial Cell Growth Supplement
(ScienCell Research Laboratories) containing 5 μg/mL
Insulin, 10 ng/mL Epidermal Growth Factor, 2 ng/mL
Fibroblast Growth Factor, 2 ng/mL Insulin-like Growth
Factor-1, 2 ng/mL Vascular Endothelial Growth Factor,
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streptomycin, and plated in 15 μg/mL fibronectin
(Sigma) pre-coated dish. U251MG cells were maintained
in DMEM medium supplemented with 1% L-glutamine,
1% penicillin/streptomycin (Stem Cell Technologies,
Vancouver, BC, Canada) and 10% FBS (Hyclone, Logan,
UT). All cell lines were cultured at 37°C in a humidified
atmosphere containing 5% CO2, and used during expo-
nential growth phase unless otherwise stated.
GBM animal model s.c. and orthotopic
All protocols involving work with live animals were
reviewed and approved by the University of British
Columbia Animal Care Committee (certificate of
approval # A07-0423). For the subcutaneous GBM
model, U251MG cells (5 × 10
6) were implanted subcuta-
neously into the backs of Rag2M mice (7-10 weeks old
females, n = 9). To generate orthotopic GBM tumors,
U251MG (7.5 × 10
4) cells were implanted into the right
caudate nucleus-putamen (ML -1.5 mm; AP +1 mm;
DV -3.5 mm) of mice (n = 5-6) using a stereotaxic injec-
tion frame (Stoelting Company, Wood Dale, IL). Ani-
mals were treated with 25 mg/kg Irinophore C™, 2 mg/
kg liposomal vincristine or 15 mg/kg doxorubicin lipo-
some (Caelyx
®,S c h e r i n g - P l o u g h ,Q C ,C a n a d a )i . v .o n
day 21, 28 and 35 after inoculation. Dosing of liposomal
vincristine and Caelyx
® resulted in less than 5% body
weight loss, while Irinophore C™ treatment did not
cause any change in body weight. Previous tests in our
laboratory have shown that the maximum tolerated sin-
gle doses for Irinophore C™, Caelyx
® and liposomal
vincristine are >120 mg/kg, 17 mg/kg and 3 mg/kg,
respectively. Irinophore C™ [16] and liposomal vincris-
tine [17] were prepared as described previously. S.c.
tumor size was measured throughout the study by cali-
per and tumor weights were extrapolated from the mea-
surements using the following formula: mg = (tumor
width^2 × tumor length)/2 [18]. Mice were injected
with Hoechst 33342 (1.2 mg/mouse; Sigma) twelve (s.c.
model) or twenty (orthotopic model) minutes prior to
sacrifice on day 42. This timing was chosen based on
previous study [8] and tests (not shown) aimed at deter-
mining the optimal timing for Hoechst 33342 injection
without saturation of the tissue and before any decrease
in Hoechst 33342 staining could be observed due to
possible metabolic elimination. All animals were termi-
nated by CO2 asphyxiation and s.c. tumors or brains
were harvested and cryopreserved in OCT (Sakura Fine-
tek, CA) on dry ice and stored at -80°C.
Hoechst 33342, Ki67, CD31, VEGFR2, EF5, Collagen IV,
NG2 and nuclei density staining and quantification
Optimal Cutting Temperature compound (OCT)-pre-
served s.c. tumors were cryosectioned using a Leica
CM1850 Cryostat (Leica, ON, Canada) and 10 μm sec-
tions were collected in the middle of each tumor. OCT
preserved brains were cryosectioned and 10 μms e c t i o n s
were collected from the Bregma +1.0 location. Sections
were fixed in a 1:1 mixture of acetone:methanol for 15
minutes at room temperature, then blocked with block-
ing buffer (Odyssey blocking buffer, Rockland, PA) for 1
hour at room temperature. Sections were stained with rat
anti-mouse CD31 antibody (1:100 dilution, PharMingen
#550274, BD Biosciences), rabbit anti-human Ki-67 (Invi-
trogen #18-0191z; 1:100), rabbit anti-human/mouse vas-
cular endothelial growth factor receptor 2 antibody
(VEGFR2; 1:100; Cell Signaling technology #2479, NEB,
Pickering, ON, Canada), rabbit anti-Collagen IV antibody
(1:400, Abcam # ab19808, Cambridge, MA) and mouse
anti-NG2 chondroitin sulfate proteoglycan antibody
(1:100, Millipore # MAB5384, Billerica, MA). Primary
antibodies were incubated on sections overnight at 4°C.
Secondary antibodies (Alexa 488 goat anti-rat #A11006,
Alexa 546 goat anti-rabbit #A-11035 and Alexa 633 goat
anti-mouse #A-21126, 1:200, Invitrogen) were incubated
for 1 hr at room temperature. Nuclei were stained with
Draq5 (Biostatus, Leicestershire, UK; 1:200) for 30 min at
37°C. Slides were mounted with PBS and imaged for
Alexa 488 (L5 filter), Hoechst 33342 (A4 filter), Alexa
546 (Cy3 filter), Cy5 (Cy5 filter) and Draq5 (Cy5 filter)
using a robotic fluorescence microscope (Leica
DM6000B, Leica, ON, Canada) and a composite color
image of these markers was produced (Surveyor software,
Objective Imaging Ltd.). Thresholds for each marker
were set using Photoshop; the threshold level was set
using a scale from 1 to 255 units, and was defined at 2
units higher than the minimal level necessary to obtain a
negative signal for non-specific staining, and was kept the
same for all sections. Acquired images were quantified
for positive pixels or colocalization (double-positive pix-
els) using an in-house segmentation algorithm, normal-
ized to the number of pixels in the tumor area and
expressed as positive fraction (positive pixels divided by
non-necrotic tumor area; MATLAB, The Mathworks,
Natick, MA). Non-necrotic tumor areas were defined by
cropping out necrotic and non-tumor tissue on the basis
of positive Ki-67 and Draq5 co-stained sections and were
quantified using the same in-house algorithm. Colocali-
zation was considered positive when two positive pixels
from one stain of interest were located within a 3 pixels
radius from one pixel of the other stain of interest. Of
note, one cell nucleus measures between 3 and 6 pixels.
Blood vessel diameter was defined by taking 10 measure-
ments/tumor section in a 15 × 15 cm box at 200% mag-
nification using Photoshop, and was expressed in pixels.
For differential analysis between the tumor’sc e n t e ra n d
periphery, the boundary between the tumor center and
periphery area was established at 20% of tumor diameter
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stained with hematoxylin and eosin for histopathology
analysis. The fraction of collagen IV-free blood vessels
was defined as Collagen IV negative/CD31 positive pixels
over total CD31 pixels. The fraction of NG2-free blood
vessels was defined as NG2 negative/CD31 positive pixels
over total CD31 pixels. The amount of basement mem-
brane empty sleeves was defined as CD31 negative pix-
els/collagen IV positive pixels divided by the total non-
necrotic tumor area.
Magnetic Resonance Imaging and Ktrans measurement in
U251MG orthotopic tumors
All magnetic resonance experiments were carried out
using a 7.0 Tesla MR scanner (Bruker, Ettlingen Ger-
many). A Bruker (Ettlingen, Germany) volume coil (inner
diameter of 7 cm) and rectangular surface coil (1.7 × 1.4
cm) was used for signal transmission and reception
respectively. The coil was tuned to the hydrogen proton
frequency (300.3 MHz). The Ktrans values were obtained
from serial images acquired to monitor changes in the
concentration of a MR-visible contrast agent (GD-DTPA;
Bayer Schering Pharma) within each pixel, during the
initial uptake and subsequent washout of the agent in the
tumor. The MRI scans follow the protocol reported by
Lyng et al. [19]; briefly, mice were anaesthetized with iso-
fluorane (5% induction, 2% maintenance), a catheter
inserted into the lateral tail vein and the animal was placed
supine with its head above the surface coil. A proton-den-
sity weighted scan was first acquired to serve as a baseline
for conversion of pixel intensity to absolute concentration
values of the contrast agent. A volume equivalent to 10 uL
per gram body weight of the contrast agent (0.03 M Gd-
DTPA in saline) was injected via the tail vein catheter in a
period of 10-15 seconds. The contrast series consisted of a
3 DR F - s p o i l e dF a s tL o wA n g l eS h o t( F L A S H )s e q u e n c e
with timing and resolution parameters as follows: echo
time/repetition time = 2.8/9.2 ms, Field of view = 1.92 ×
1.92 × 1.6 cm, Matrix size = 128 × 128 × 16 cm, acquisi-
tion time per image = 9.45 seconds. Twenty baseline scans
were acquired before contrast agent injection and 250
scans were acquired afterwards, resulting in a total acquisi-
tion time of 43 minutes. The concentration-time curve for
each pixel was fit to a two-compartment Kety model [20]
which describes the pharmacokinetics of the contrast
agent using three parameters: ve (volume of extracellular
extravascular space), Ktrans (volume transfer constant
between the vasculature and tissue compartment) and Vp
(fractional volume of the vascular compartment).
In vitro endothelial cell exposure and nuclei count
For proliferative conditions, Dermal Human MicroVas-
cular Endothelial Cells (d-HMVEC; 600 cells/well) and
Human Brain Microvascular Endothelial Cells
(HBMEC; 5000 cells/well) were plated in black 96-well
plates (Optilux™, BD Biosciences, Mississauga, ON,
Canada) and drugs were added the day after. For non-
proliferative conditions, d-HMVEC cells (5000 cells/
well) and HBMEC (50000 cells/well) were plated in
black 96 well plates and drugs were added four days
after. Irinotecan (Sandoz, QC, Canada), SN-38 (LKT
Laboratories, MN, USA), vincristine (Novopharm, ON,
Canada), docetaxel, paclitaxel (Taxol
®; Bristol Myers
Squibb Canada, QC, Canada) and doxorubicin (Adria-
mycin
TM/MC,P f i z e r ,Q C ,C a n a d a )w e r ea d d e di nc o n -
centrations ranging from 1-100,000 picoMolar on cells
and replaced daily for 7 days. At the end of drug treat-
ment, cells were fixed with 3.5% paraformaldehyde
(Electron Microscopy Sciences, PA) for 15 minutes at
-20°C, permeabilized with 0.1% Triton (Perkin-Elmer,
MA) in PBS for 10 minutes at room temperature,
blocked for 1 hr at 4°C (Odyssey blocking buffer,
Rockland, PA) and incubated overnight with Ki67 anti-
body (Invitrogen #18-0191z; 1:100 dilution in blocking
buffer). Cells were then incubated with Anti-rabbit
A l e x a4 8 8s e c o n d a r ya n t i b o d y( M o l e c u l a rP r o b e
#A11034, Invitrogen; 1:200 in blocking buffer) for 1 hr
at room temperature. Nuclei were stained with Draq5
dye (Biostatus, Leicestershire, UK; 1:200 in PBS) for 30
min at 37°C. Twenty fluorescent photographs/well
(Alexa 488 emission: 475 nm, excitation: 535 nm;
Draq5 emission: 620 nm, excitation: 700 nm) were
taken at 10 × magnification using an InCell Analyzer
1000 (Amersham Bioscience) and the total nuclei
count (Draq5 stained nuclei) as well as Ki67 expressing
nuclei count (Draq5 and Alexa 488 double stained
nuclei) were quantified using InCell Developer Tool-
box software (Amersham Bioscience, GE Healthcare,
Baie d’Urfe, QC, Canada). Dose-response curves gener-
ated from total nuclei count were used to calculate
drug concentrations causing a decrease in endothelial
cell nuclei count by 20% (fraction affected: Fa = 0.2),
50% (Fa = 0.5), 75% (Fa = 0.75) and 90% (Fa = 0.9)
and compared for both proliferative and non-prolifera-
tive cells. All data points represent the average of 3
independent experiments in triplicate +/- S.E.M.
Statistical analysis
All statistical data was collected using GraphPad Prism
(San Diego, CA). Because all treatment drugs were chosen
based on previous rationale justifying their inclusion in the
study, the experimental design should not be regarded as a
screening assay and statistical analysis was done using the
single comparison non-parametric two-tailed Mann Whit-
ney test and no correction was made for multiple compar-
isons. All data are expressed +/- S.E.M.
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Irinophore C™, Caelyx
® and liposomal vincristine inhibit
tumor growth and increase Hoechst 33342 delivery in
subcutaneous GBM tumors
Rag2M mice bearing s.c. U251MG tumors (n = 9) were
treated i.v. weekly for 3 weeks with 25 mg/kg Irinophore
C™, 15 mg/kg Caelyx
® and 2 mg/kg liposomal vincris-
tine. Tumor growth was monitored during the entire
treatment period, and tumors were harvested 7 days
after the last treatment. As noted in Figure 1a, the three
drugs inhibited tumor growth significantly compared to
untreated control (p < 0.05-0.001). At the end of the
study (day 42), the weight of treated tumors ranged
from 34 to 80 mg compared to an average of 502 mg
for untreated control animals. A representative tumor
section (H&E) derived from each treatment group is
also provided in Figure 1a. The total non-necrotic
tumor area (excluding necrotic and non-tumor area)
measured in number of image pixels for each treated
group is summarized in Figure 1b. The measurements
of area of viable tumor tissue correlated with the tumor
weight measurement and was significantly reduced for
all treatment groups (compared to untreated tumors; p
< 0.0001). The proliferation marker Ki67 was used to
estimate the fraction of viable cells undergoing active
proliferation within the tumor (positive Ki67 staining
divided by total viable tissue, expressed as Ki67 positive
fraction). Liposomal vincristine had no apparent effect
on the Ki67 staining compared to control tumors.
Treatment with Irinophore C™ caused a 2-fold decrease
in Ki67 staining (p < 0.01). In contrast, a significant (p <
0.01) increase in Ki67 staining was observed in tumors
from animals treated with Caelyx
® (Figure 1b). It should
be noted that Caelyx
® treatment was also associated
with enlarged tumor cell nuclei (see arrow heads in
insert H&E image Figure 1a) and this may suggest that
the treatment promoted cell cycle arrest [21]. This
observation is in accordance with previously published
findings on the effects of doxorubicin on cell cycle
[22-24] and the fact that cellular Ki67 antigen has been
shown to accumulate in some types of cell cycle arrest
[25]. Finally, a decrease in number of cell nuclei per
area (nuclei density) with a concomitant increase in
connective tissue was observed by examination of the
H&E stained sections in tumors from mice treated with
Irinophore C™.
The effects of the selected liposomal drugs on tumor
blood vessels were also evaluated. As summarized in
Figure 1c, the CD31 staining (positive CD31 fraction)
did not change significantly when comparing tumors
from control animals to those from treated animals.
Prior to sacrifice, animals were injected with Hoechst
33342, a marker for tumor perfusion that was previously
validated by correlation with Ktrans measurements [8].
Total Hoechst 33342 staining in viable tissue (positive
Hoechst 33342 fraction) was increased in the tumors
obtained from treated animals (p < 0.01-0.001; Figure 1c).
CD31 and Hoechst 33342 co-staining was measured to
provide an indication of changes in functional blood
vessels [8]. The results, summarized in Figure 1c, indicate
that the number of functional blood vessels increased
significantly (p < 0.05) in Caelyx
® treated tumors while
there were no significant changes observed in tumors
from Irinophore C™ and liposomal vincristine treated
animals.
Irinophore C™, Caelyx
® and liposomal vincristine inhibit
tumor growth and decrease Hoechst33342 delivery in
orthotopic GBM tumors
Rag2M mice (n = 5 or 6) were inoculated with U251MG
cells orthotopically (see Methods) and 21 days later the
animals were treated i.v. (once weekly for 3 weeks) with
25 mg/kg Irinophore C™, 15 mg/kg Caelyx
® and 2 mg/
kg liposomal vincristine. Forty-two days after cell inocu-
lation, animals were sacrificed and their brains har-
vested. A representative tissue section (Hematoxylin and
Eosin; H&E) showing the site of tumor growth (dark
blue) within the brain of treated animals is provided for
each treatment group in Figure 2a. Insert images have
been included to show that following treatments, the
tumor nuclear density drops slightly when compared to
untreated controls. The average total non-necrotic
tumor tissue in the tumor area for each treatment
group was quantified to provide a measure of efficacy
(Figure 2b). There was a significant reduction in tumor
area for all treatment groups when compared to con-
trols (p < 0.0001). In contrast to the results obtained
with the s.c. glioma model, there was no significant
changes in Ki67 staining observed following treatment
(Figure 2b).
Prior to sacrifice, animals were also injected with
Hoechst 33342. In tumors from untreated control mice,
Hoechst 33342 staining was significantly greater in
tumor tissue compared to matched regions of normal
brain tissue (0.398 +/- 0.083 and 0.023 +/- 0.015 pixels/
unit area, respectively; p < 0.01; data not shown). This
staining pattern has been described elsewhere [26,27]
and is consistent with the fact that Hoechst 33342 does
not cross the blood-brain barrier. Interestingly, the data
summarized in Figure 2c show that Hoechst 33342
staining in the orthotopic tumor tissue from animals
treated with the liposomal drugs was significantly
reduced (p < 0.01) when compared to tumors from
control animals. The decrease in Hoechst 33342 staining
in orthotopic tumors from treated animals was in
marked contrast to treatment-induced increases in
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the same cell line (U251MG) and grown subcutaneously
(Figure 1c).
No significant changes in overall CD31 staining (pix-
els/unit area) (Figure 2c) were noted in the orthotopic
tumors obtained from treated animals (compared to
controls). However, CD31/Hoechst 33342 co-staining
was significantly reduced (p < 0.01-0.05) in tumors
from treated animals when compared to control animals
(Figure 2c). Moreover, treatment of orthotopic tumor
Figure 1 Irinophore C™, liposomal vincristine and Caelyx
® significantly inhibits tumor growth, decreases proliferation and increases
tumor perfusion in subcutaneous GBM tumors. a) Representative H&E sections of tumors from each treatment group show the efficacy of
the treatments in controlling tumor growth. Arrow heads indicate enlarged nuclei associated with Caelyx
® treatment. Tumor weights were
calculated on the basis of caliper measurements; arrows indicate the treatment days. The Irinophore C™ statistical significance is indicated by
bottom stars, while Caelyx
® and liposomal vincristine statistical significances are indicated by top stars (*p-value ≤ 0.05; **p-value ≤ 0.01; ***p-
value ≤ 0.001) b) The area of viable tissue in tumor sections following treatment was expressed in number of pixels and correlates well with
tumor volumes (■, left axis). The fraction of viable, actively proliferating cells (■, right axis) in the tumors was significantly decreased by
Irinophore C™. Ki67 staining was also increased in Caelyx
®-treated tumors. c) Hoechst 33342 perfusion in the tumors was increased significantly
by Irinophore C™ and Caelyx
® treatment (■, left axis). The number of endothelial cells per unit area of viable tissue was unchanged by the
treatments (■, right axis); however, the fraction of endothelial cells that were perfused (CD31 and Hoechst 33342 positive; □, right axis) was
increased by treatment with Caelyx
®. Statistical significances are indicated (*p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001).
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with a significant (p < 0.05) increase in CD31 staining
in the center of tumors when compared to untreated
tumors (Figure 2d; p < 0.05).
Assessing vascular normalization in GBM tumors from
animals treated with Irinophore C™, Caelyx
® or liposomal
vincristine
Several structural determinants, described as indicators
of vascular normalization [28-30], were assessed in the
orthotopic and s.c. GBM tumor models following treat-
ment and these data were compared to tumors from
untreated control animals. The parameters evaluated
included: (i) the extent of discontinuous basement mem-
brane (collagen IV-free CD31 pixels) in the tumor tis-
sue, (ii) the fraction of pericyte-uncovered blood vessels
(NG2-free CD31 pixels) in the tumor tissue and (iii) the
blood vessel diameter. Furthermore, the proportion of
empty basement membrane sleeves (CD31-free collagen
IV pixels) was evaluated as an indication of regression
of pre-existing blood vessels [9]. Treatment-induced
changes in these factors are summarized in Figures 3
(s.c. tumors) and 4 (orthotopic tumors).
In s.c. GBM tumors, the fraction of NG2-free blood
vessels was reduced by 25% in tumors from animals
treated with Irinophore C™ (p < 0.05; Figure 3a).
Decreases in NG2-free blood vessels were also noted in
tumors from animals treated with Caelyx
® (p = 0.071)
or liposomal vincristine (p = 0.121); but the effects were
not considered significant. The number of collagen IV-
free blood vessels was decreased in s.c. tumors from ani-
mals treated with Irinophore C™ or Caelyx
® (41-75%
Figure 2 Orthotopic GBM tumors treated with Irinophore C™, liposomal vincristine and Caelyx
® are significantly smaller than
untreated controls. a) Representative H&E images of brain sections from mice in each treatment group show that the area of tumor tissue
(dark blue) from treated animals are smaller than untreated controls. b) Tumor areas were quantified in number of pixels, and used as a measure
of treatment induced reduction of the tumor mass (■, left axis). No significant changes in proliferative activity (■, right axis) were observed. c)
Hoechst 33342 staining was reduced significantly following treatments with the three liposomal treatments (■, left axis). The total number of
endothelial cells per unit area of viable tissue (■, right axis) was unchanged across all groups, but the fraction of endothelial cells that were co-
stained with Hoechst 33342 was significantly reduced (□, right axis). d) The density of endothelial cells (positive CD31 pixels divided by periphery
or center tumor area pixels) in the center of tumors treated with Irinophore C™ was significantly higher compared to control tumors (□). No
changes in endothelial cell density were seen in the total tumor area (■) or the periphery of tumors (■). Statistical significances are indicated (*p-
value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001). Non-significant trends are indicated (&p-value = 0.067).
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Page 7 of 18decrease; p < 0.05-0.001; Figure 3a). Blood vessel dia-
meter was also reduced (32%-51%; p < 0.001) in s.c.
tumors from all treatments groups. Finally, the number
of empty basement membrane sleeves in tumors from
Irinophore C™ and Caelyx
® treated animals was
increased 3.4- to 3.8-fold following treatment (p <
0.0001). A similar effect was noted for tumors from
animals treated with liposomal vincristine, but the
effect was not considered significant (p = 0.054).
Representative immunofluorescence micrographs high-
lighting the effects of Irinophore C™ treatment on the
tumor vasculature of s.c. U251MG tumors (Figure 3c)
compared to untreated tumor (Figure 3b) are provided
to support the results summarized in Figure 3a.
Similar results were obtained when evaluating the
orthotopic U251MG tumors from treated animals
compared to controls. In addition, histological assess-
ments of brain tissue surrounding the tumor allowed
Figure 3 Irinophore C™, liposomal vincristine and Caelyx
® treatments are associated with vascular normalization of the tumor
vasculature in subcutaneous GBM tumors. a) The diameters of tumor blood vessels were reduced significantly by all three treatments
compared to control tumors (■, left axis). The fraction of NG2-free CD31 pixels (■, right axis), collagen IV-free CD31 pixels (■, right axis) were
reduced in Irinophore C™ treated tumors indicating that fewer immature vessels are present following treatments. The proportion of empty
basement membranes (CD31 free-collagen IV staining; □, right axis) in the viable tissue was also reduced by all liposomal treatments. b and c)
Representative and merged images of CD31, Collagen IV and NG2 staining for control tumors (b) and tumors from Irinophore C™ treated mice
(c). A reduction in blood vessel diameter (CD31; green) and an increase in basement membrane coverage of blood vessels (collagen IV; yellow)
following treatment can be seen. Following Irinophore C™ treatment, more pericytes are present (NG2; red) and more endothelial cells are
associated with the pericytes (merged image, green and red). Treatment with Irinophore C™ also results in an increase in empty basement
membrane sleeves (i.e. CD31 free-collagen IV; yellow). The entire image represents non-necrotic and viable tissue. Statistical significances are
indicated (*p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001; ****p-value ≤ 0.0001). Non-significant trends are indicated (&p-value = 0.121;
&&p-value = 0.071; &&&p-value = 0.054).
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brain tissue. The fraction of collagen IV-free blood ves-
sels in normal brain (0.049 +/- 0.015) was 69% lower (p
< 0.05) than that observed in tumor tissue from control
untreated animals (0.160 +/- 0.033), indicating that the
organization of the basement membrane architecture is
decreased in the tumor compared to normal tissue (data
not shown). Tumors from animals treated with Irino-
phore C™ showed a significant 71% (p < 0.05) decrease
in the fraction of collagen IV-free blood vessels when
compared to tumors from control animals (Figure 4a).
A similar effect was observed in tumors from animals
treated with Caelyx
®, but the effect was not considered
significant (p = 0.064). In normal brain tissue, blood
vessel diameters were 54% smaller (4.9 +/- 0.5 pixels; p
< 0.0011) than blood vessel diameters observed in
orthotopic tumor tissue obtained from untreated ani-
mals (10.9 +/- 0.6 pixels; data not shown). Orthotopic
tumors from animals treated with Irinophore C™ or
Caelyx
® exhibited a reduction in blood vessels diameters
of 39% (p < 0.01; Figure 4a) when compared to control
tumors. In contrast to results obtained with the s.c.
tumors of treated animals, the level of empty basement
membrane sleeves (Collagen IV-free CD31 staining) in
the orthotopic tumors did not change following treat-
ment (Figure 4a). It should be noted that the level of
empty basement membrane sleeves in the normal brain
tissue (0.035 +/- 0.009) was found to be similar to that
measured in orthotopic tumor tissue from untreated
animals (0.047 +/- 0.009) (data not shown). Treatments
did not induce significant changes in fraction of NG2-
free blood vessels (Figure 4a). The fraction of NG2-free
vessels in the normal brain could not be evaluated as
NG2 proteoglycan was found at the surface of polyden-
drocytes, a subpopulation of glial cells found in the
brain [31]. Representative immunofluorescence micro-
graphs illustrating the effects of Irinophore C™ treat-
ment on the orthotopic tumor vasculature are provided
in Figure 4b. Normal brain tissue sections are shown in
Figure 4c for comparison.
Magnetic resonance imaging-measured changes in
vascular permeability/flow (Ktrans)
The results summarized thus far are consistent with the
idea that following treatment of animals bearing GBM
tumors with lipid-based nanopharmaceutical formula-
tions of vincristine, doxorubicin and irinotecan, there is
a “normalization” of blood vessel structure. When con-
sidering these effects along with the antitumor activity,
the greatest effects were observed following treatment
with Irinophore C™. In order to confirm the idea of a
Irinophore C™-induced vascular normalization, non-
invasive magnetic resonance imaging was used to assess
Ktrans, a volume transfer constant of a solute between
the blood vessels and extra-cellular tissue compartment,
in orthotopic tumors grown in untreated and Irinophore
C™treated mice. The median values of Ktrans for the
tumors within the control and treated groups have been
summarized Figure 5. The results demonstrate that the
median Ktrans value in untreated tumors was ~7 times
greater than in treated tumors (0.0232 and 0.0034 ml/g/
min, respectively, p < 0.05). It should be noted that the
values for Ktrans in tumors from untreated animals were
more variable when compared to the tumors from trea-
ted mice (s.e.m ± 0.010 and ± 0.0003, respectively).
In vitro studies on endothelial cells mimicking the
extended drug exposure achieved when using liposomal
drug delivery formulations
In an attempt to better understand the effects of liposo-
mal formulations used here on tumor vasculature, an in
vitro endothelial cell assay was used to assess the impact
of extended drug exposure. It is well established that
these liposomal formulations engender significant
increases in plasma drug concentrations over extended
time periods following intravenous administration [7,11].
Thus, an extended drug exposure protocol was used to
assess the effects of drugs in a model representative of
the endothelial cells forming vessels in the subcutaneous
or brain microenvironment. Dermal Human MicroVas-
cular Endothelial Cells (d-HMVEC) and Human Brain
Microvascular Endothelial Cells (HBMEC) were cultured
under proliferative or non-proliferative conditions and
exposed to the indicated drugs for 7 days. As illustrated
in Figure 6a, the total nuclei count and the number of
nuclei expressing the Ki67 proliferation marker were
quantified using high content screening (Incell analyzer
1000) to discriminate between cytotoxic (reduction in
total number of nuclei) and cell proliferation inhibitory
effects (reduction in Ki67 expressing fraction). Under
proliferative conditions, the nuclei count for the endothe-
lial cell lines used increased up to 3-fold over the 7 day
time period. The Ki67 expressing nuclei fraction ranged
from 42 to 68% over this time frame (Figure 6a and 6b).
Under non-proliferative conditions, the nuclei count for
cell lines (d-HMVEC and HBMEC) remained unchanged
from day 1 to day 7, and the Ki67 expressing nuclei frac-
tion ranged from 7 to 31% (Figure 6a and 6b).
The activity of the drugs against the cells maintained
under the two conditions was compared to assess the
selectivity of the drugs for proliferating endothelial cells
compared to non-proliferating endothelial cells. For all
drugs used in this study, the dose-response curves for
Ki67 expressing nuclei of proliferating cells matched
the ones for the total nuclei count, suggesting
that the drugs tested were cytotoxic rather than
Verreault et al. BMC Cancer 2011, 11:124
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Page 9 of 18Figure 4 Irinophore C™, liposomal vincristine and Caelyx
® treatments are associated with vascular normalization of the tumor
vasculature in orthotopic GBM tumors. a) Vessel diameters (■, left axis) and the fraction of collagen IV-free CD31 pixels (■, right axis) in
orthotopic GBM tumors were reduced by Irinophore C™ and Caelyx
®. However, no changes were seen in the fraction of NG2-free CD31 positive
endothelial cells (■, right axis) or Collagen IV-free CD31 positive endothelial cells (□, right axis). b) Representative images from untreated and
Irinophore C™ treated tumors; similar images for normal brain tissue are shown for comparison. (c) Blood vessel diameters (CD31; green) are
reduced by Irinophore C™ treatment. The basement membrane (collagen IV; yellow) is partially restored by treatment with Irinophore C™. The
entire image represents non-necrotic and viable tissue. Statistical significances are indicated (*p-value ≤ 0.05; **p-value ≤ 0.01). Non-significant
trends are indicated (&p-value = 0.064).
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Page 10 of 18anti-proliferative. Representative dose-response curves
for d-HMVECs and HBMECs exposed to SN-38, the
active metabolite of irinotecan, under proliferative and
non-proliferative conditions are shown in Figure 6b.
The data indicates that SN-38 is significantly more
active against proliferating endothelial cells then non-
proliferating cells. In an effort to highlight differences in
drug activity under proliferating and non-proliferating
conditions, drug concentrations decreasing d-HMVEC
total nuclei count by 20% (fraction affected: Fa = 0.2),
50% (Fa = 0.5), 75% (Fa = 0.75) and 90% (Fa = 0.9) were
calculated from the dose-response curves and compa-
red for both proliferative and non-proliferative cells
(Figure 7). For example, results obtained at Fa = 0.75
indicate that the greatest differential effects were
observed when using SN-38 and vincristine, where the
drug dose required to achieve a 75% decrease in nuclei
count under proliferation conditions were at least 100-
and 90.9-times lower, respectively, than the drug dose
required to achieve the same effect level under non-pro-
liferative conditions. These effects were much greater
than those seen using the positive control compounds
docetaxel and paclitaxel. In contrast, there was little or
no difference in the concentrations of irinotecan or dox-
orubicin required to achieve a Fa of 0.75 under prolifer-
ating and non-proliferating conditions. Similar results
were obtained when using HBMECs (Figure 8). It
should be noted that the drug doses required to achieve
a Fa value of 0.5 for SN-38 and vincristine was 45 to
5000 times greater for U251MG glioblastoma cells when
compared to the proliferating endothelial cells (data not
shown) and the increased specificity for proliferating
endothelial cells has been noted previously for paclitaxel
and SN-38 when compared against human colorectal
and breast cancer cells [32,33].
Discussion
Studies over the last few decades have established that
liposomal formulations of selected antineoplastic agents
can be more effective than the same drug administered
in free form. Liposomal formulations of anticancer
drugs are known to have long circulation half-lives in
vivo, and release the drug slowly over time [7,11]. Thus,
the pharmacological properties of a drug given in its
free form (e.g. via bolus injection or slow infusion) is
changed dramatically by encapsulation in liposome. As a
result, one might anticipate that the use of liposomal
drugs will expose tumors to drugs for extended periods
of time when compared to treatment with the free drug.
This, of course, is well established in the literature and
has been explained on the basis of the enhanced perme-
ability and retention effect known to promote accumula-
tion of intravenously administered liposomal drug
formulations in tumors [34]. What is often not consid-
ered in studies with liposomal formulations is that these
formulations constantly release the associated drug
while in the circulation compartment, thereby extending
the presence of the drug in the plasma compartment.
This study tries to address whether part of the treat-
ment benefits could be attributed to direct effects of the
free drug (available in the blood compartment) on
tumor vascular endothelial cells. The fact that these
drug formulations are active against proliferating vascu-
lature was anticipated, but not demonstrated to date.
Liposomal drug formulations are known to accumulate
and release drugs in close proximity to tumor blood ves-
sels [14,15]. More intriguing, however, is the possibility
that exposing the tumor vasculature to low concentra-
tions of drug for extended periods may produce effects
that are comparable to the vascular normalization effects
described in the context of anti-angiogenic therapy
[9,10] as discussed below.
In the present study, it is demonstrated that Irino-
phore C™, Caelyx
® and liposomal vincristine are effec-
tive against GBM grown subcutaneously or
orthotopically (in the brain). The tumor masses in trea-
ted animals were significantly smaller compared to con-
trol (p < 0.001; Figure 1a), indicating that the liposomal
drugs used in this study are potent against GBM,
regardless of the site of tumor growth. Analysis of the
tumor tissue, and in particular the vascular morphology,
also indicates that treatments affected the tumor vascu-
lature to various degrees. Overall, Irinophore C™
impacted the vasculature to a greater extent than the
other formulations, and generated tumors with blood
vessels that were morphologically more mature. In the
subcutaneous model, Irinophore C™ restored the base-
ment membrane architecture, increased the pericyte
coverage and reduced blood vessel diameters. The data
Figure 5 Irinophore C™ reduced Ktrans measures compared to
values obtained from control orthotopic tumors. Individual and
median (thick line) Ktrans values for untreated and Irinophore C™
treated orthotopic tumors with standard error of the mean (thin
line). Statistical significance is indicated (*p-value ≤ 0.05).
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normal state. In the more clinically relevant orthotopic
model, Irinophore C™ treatment restored the basement
membrane architecture and reduced blood vessel dia-
meters of the tumor vasculature, again suggesting a
restoration of the vessel architecture to a more normal
state. Irinophore C™ treatment also increased the quan-
tity of vessel staining in the center of tumors, suggesting
a more homogenous distribution of blood across the
entire tumor. Further, Irinophore C™ reduced Ktrans
Figure 6 d-HMVEC and HBMEC were plated under proliferative conditions or non-proliferative conditions. a) Representative composite
color images of d-HMVEC cells are shown; Draq (blue; nuclei), and Ki67 (green). Under proliferative conditions, the number of nuclei and Ki67
positive staining are similar; whereas under non-proliferative conditions, the number of nuclei with positive Ki67 staining is much lower. b) Total
nuclei count and Ki67 expressing nuclei fraction of untreated cells for both cell lines under proliferative and non-proliferative conditions on day
1 and day 7 after plating (3 independent experiments; 3-21 replicates per experiment). Cells were exposed for 144hrs to increasing drug
concentrations (1-100,000 picoM). Total nuclei count as well as nuclei expressing Ki67 expressing counts were normalized to counts obtained
from control untreated cells. Representative data for d-HMVEC and HBMEC exposed to SN-38 is shown (3 independent experiments; 3 replicates
per experiment +/- SEM). Statistical significance is indicated (*p-value < 0.0001) between total nuclei count of proliferative and non-proliferative
cells.
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(DCE)-MRI studies significantly. Based on changes in
vessel morphological appearance, the drop in Ktrans
values was interpreted as a decrease in vessel permeabil-
ity [35], and is consistent with the suggestion that Irino-
phore C™ treatment improved vascular function in the
tumor. The larger variability in Ktrans values determined
in tumors from control animals reflects the random nat-
ure of chaotic and leaky blood vessels in individual
tumors [36]. It had already been established in s.c
tumors that Hoechst 33342 could be used as a marker
for tumor vessel function by validation with Ktrans mea-
surements [8], but this had not been done for the ortho-
topic GBM tumor described here. It is shown here that
the observed reduction in Hoechst 33342 staining after
treatment while total CD31 staining remained constant
correlates with a reduction in Ktrans measures. Taken
together, these observations strongly suggest an
improvement in vascular function. The tumor blood
vessels in tumors from animals treated with Irinophore
C™ behave more like vessels in the normal brain where
the blood-brain barrier is intact.
The concept of ‘blood vessel normalization’ was first
postulated in the 70s [37] and more recently, the clinical
potential of vascular normalization has been described
[9,10]. As with most solid tumors, the microvasculature
of gliomas is characterized by tortuous and fenestrated
vessels with diameters that are larger than normal [38]
and discontinuous basement membrane which rarely
encloses pericytes [39]. In glioma [28,29,40], antiangio-
genic therapies can stop the growth of tumor vessels,
prune immature and inefficient tumor vessels and nor-
malize surviving vasculature by increasing the fraction
of pericyte-covered vessels, restoring the abnormally
thick and irregular basement membrane and reducing
the high vascular permeability of these vessels [9,10]. In
Figure 7 Proliferating HMVEC cells are more sensitive to SN-38, docetaxel, paclitaxel, doxorubicin and vincristine than non-
proliferating cells. Concentrations at which a Fa of 0.2-0.9 was observed in d-HMVEC total nuclei count for both proliferative and non-
proliferative conditions. The fold difference in drug concentration required to achieve the specified Fa is indicated above each pair of columns.
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was defined by changes in vascular permeability (Ktrans
values), microvessel volume and circulating collagen IV.
It was found that this index was closely associated with
overall survival and progression-free survival in response
to Cediranib, a pan-VEGFR inhibitor [40]. Pre-clinically,
the delivery of temozolomide in an intracerebral model
of glioma increased after treatment with the angiogen-
esis inhibitor SU5416. This drug restored capillary archi-
tecture and decrease interstitial fluid pressure [41]. Such
studies offer strong evidence that the tumor vasculature
in GBM is a valid target, and that therapies which ‘nor-
malize’ tumor vasculature may improve the delivery of a
second drug at some point in the treatment regimen.
The studies described here, together with an earlier
publication [8], offer strong evidence that liposomal for-
mulations of selected drugs,a n de s p e c i a l l yI r i n o p h o r e
C™, induce a normalization of the tumor vasculature.
In this study, collagen IV and NG2 were used as mar-
kers for basement membrane and pericytes, respectively.
However, there is no consensus in the field for a defini-
tive marker of these parameters. Other markers used to
evaluate basement membranes include nidogen or lami-
nin, and desmin or a-smooth muscle actin for pericytes
[9,30]. These caveats notwithstanding, the morphological
changes observed were associated with changes in
Hoechst 33342 uptake in the tumor and when using this
parameter, remarkably different results were obtained
Figure 8 Proliferating HBMEC cells are more sensitive to SN-38, docetaxel, paclitaxel, doxorubicin and vincristine than non-
proliferating cells. Concentrations at which a Fa of 0.2-0.9 was observed in HBMEC total nuclei count for both proliferative and non-
proliferative conditions. The fold difference in drug concentration required to achieve the specified Fa is indicated above each pair of columns.
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orthotopic). In the subcutaneous model, the liposomal
treatments increased the amount of Hoechst 33342
staining in the tumor tissue (Figure 1c), while in the
orthotopic tumors Hoechst 33342 staining was reduced
(Figure 2c). As noted above, treatment effects were simi-
lar if blood vessel morphology parameters were used as
a measured endpoint. While initially surprising, the
Hoechst 33342 uptake data may actually be consistent
with restoration of the blood-brain barrier, which is
more impermeable to Hoechst 33342. It is well estab-
lished that Hoechst 33342 is a p-glycoprotein substrate
[42]. It does not accumulate in normal brain tissue
because it cannot cross the blood brain barrier, but it is
present in untreated orthotopic brain tumors which
exhibit leakier blood vessel. This idea was further con-
firmed by Ktrans measurements, which strongly sug-
gested a vasculature normalization induced by
Irinophore C™. This interpretation suggests that
Hoechst 33342 is not an appropriate marker for tumor
perfusion in orthotopic glioma models, as it was pre-
viously used in a s.c. tumor model [8]. It does, however,
function as a permeability marker for perfused tumor
associated blood vessels, which is reduced upon normal-
ization. The impact of vascular normalization on tumor
perfusion in orthotopic GBM tumors could not be
assessed in the present study because MRI Ktrans data
and Hoechst 33342 staining data are not direct mea-
sures of perfusion in the brain tumor. However, data
obtained in the subcutaneous model suggest that treat-
ment with liposomal drugs does not reduce tumor per-
fusion, as measured by CD31/Hoechst 33342 double
staining, and may even increase it, as suggested by data
obtained from Caelyx
®-treated s.c. tumors. Studies to
measure the delivery of a second drug that can cross the
BBB in liposomal drug-treated tumors are underway and
will provide an indication of the impact of vascular nor-
malization on vessel perfusion in the orthotopic model.
The idea that liposomal formulations of anti-cancer
drugs, in addition to having a direct cytotoxic effect on
the tumor cells, may also act as through anti-angiogenic
mechanisms is intriguing. It seems reasonable to suggest
that the extended drug release characteristics associated
with the liposomal drug formulations used in this study
[ 7 , 1 1 ]m a yh a v ee f f e c t so nb l o o dv e s s e l si nam a n n e r
similar to metronomic dosing schedules - i.e. frequent,
low dose administration of drugs with no prolonged
drug-free breaks [43]. Metronomic dosing is now
acknowledged to act specifically on the proliferating
endothelial cells of tumor blood vessels [44] and was
more recently shown to improve tumor perfusion and
to decrease hypoxia in a pancreatic tumor model [45].
To examine this hypothesis, an in vitro assay was used
to evaluate the activity of irinotecan, doxorubicin and
vincristine (the drugs encapsulated by liposome exam-
ined in this study) against proliferating endothelial cells.
The assay was adapted from one developed by Bocci
et al. to examine the effects of metronomic drug expo-
sure against endothelial cells [33]. Previous reports sug-
gest that docetaxel and paclitaxel have potent activity
against endothelial cells in an in vitro metronomic dos-
ing regime [32,33,46], so these drugs were included in
the assay as positive controls. The effects of SN-38 were
also evaluated in the assay because SN-38 is a more
active metabolite of irinotecan generated by tissue and
plasma carboxylesterases in vivo [47,48]. Further it has
already been established that following treatment with
Irinophore C™, high levels of SN-38 are maintained in
the plasma compartment for extended time periods [7].
SN-38 levels may play an important role in the anti-can-
cer activity of Irinophore C™.
The in vitro metronomic dosing assay presented in
Figures 7 and 8 suggest that vincristine and SN-38, like
the taxanes (docetaxel or paclitaxel), are highly active
against proliferating endothelial cells (Figure 6a-b). In
contrast, free irinotecan has little specificity for prolifer-
ating endothelial cells over non-proliferating cells
in vitro. The data for free vincristine corroborate the
effects on tumor vasculature seen with the liposomal
form of the drug used here, while the results obtained
with free irinotecan, which is not specific for proliferat-
ing endothelial cells, is actually contradictory. Irinophore
C™ was the most active of the three liposomal formula-
tions used. The results in Figure 7 and 8 would strongly
suggest that the activity of Irinophore C™may be
explained by the high plasma levels of SN-38 generated
following administration of the formulation [7,16]. Thus
it can be concluded from the studies presented here
that the active metabolite of irinotecan, SN-38, may be
the agent promoting vascular normalization in the mod-
els used here.
Interestingly, the in vitro assay suggests that doxorubi-
cin should have little specificity on proliferating
endothelial cells, yet i.v. administration of Caelyx
®
resulted in effects on the tumor vasculature that were
comparable to those seen following administration of
Irinophore C™. The reasons for this are unclear at pre-
sent but may be related to disruptions in the production
of hypoxia-induced VEGF caused by doxorubicin [49].
Previous studies completed using the rat intracranial 9L
tumor model treated with a formulation of doxorubicin
comparable to that used here [15] showed the presence
of vascular breakdown and hemorrhage 48 hours after
treatment. In contrast, the results summarized here
were obtained using tumors harvested one week after
the final treatment; thus the data here may reflect late
effects on tumor vasculature. Further, 9L is a gliosar-
coma cell line which exhibits a slower doubling time
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(20.9 hrs; data not shown) used in this study. The
resulting 9L tumors are also histological distinct [50]
when compared to the U251MG model. These differ-
ences will likely impact how tumors respond to agents
capable of promoting vascular normalization. Studies
assessing how vascular functions change in relationship
to tumor growth rate are currently being completed.
Conclusion
In aggregate, data from this study indicates that liposomal
formulations of irinotecan, doxorubicin and vincristine
exert anti-angiogenic effects, as measured by endpoints
assessing increases in mature blood vessels and improved
vascular function. The normalization of tumor vessels
appears to be transient in nature [36] but may create a
window where blood flow is improved, leading to an
opportunity to improve drug delivery for other drugs. The
fact that all three formulations were therapeutically active
in the orthotopic model suggests that vascular normaliza-
tion did not prevent the drugs from accessing tumor cells,
despite the fact that our interpretation of data obtained
from Hoechst 33342 suggests a reduction in vessel perme-
ability. Data from our laboratory showed that once irinote-
can is released from the lipid carrier, the drug and its
active metabolite SN-38 are capable of crossing a normal
blood-brain barrier (Verreault M, Strutt D, Masin D, Ana-
ntha M, Waterhouse D, Yapp DT and Bally MB: Irino-
phore C™, a lipid-based nanoparticulate formulation of
irinotecan, is more effective than free irinotecan when
used to treat an orthotopic glioblastoma model, submitted
for publication in March 2011). Vincristine was also
shown to be able to cross a normal blood-brain barrier
[51]. Thus, it can be speculated that vascular normaliza-
tion would increase the delivery of drug that have disso-
ciated from the liposome across the tumor vasculature,
allowing higher levels of drug to diffuse into a greater
volume of tumor tissue. Studies assessing the conse-
quences of liposomal drug-induced vascular normalization
on the delivery of a second drug capable of crossing the
blood-brain barrier will provide important information
regarding the impact of tumor vessel permeability on drug
delivery. In the case of GBM, an obvious choice of such a
drug is temozolomide. Pre-clinical studies to assess the
impact of Irinophore C™ treatments on the delivery of
temozolomide are currently on-going.
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